Title:
Accuracy of Auto-Titrating CPAP to Estimate the Residual Apnea-Hypopnea Index in Patients with Obstructive Sleep Apnea on Treatment with Auto-Titrating CPAP.

Authors:
Himanshu Desai M.D.¹, Anil Patel M.D.², Pinal Patel M.B.B.S.¹, Brydon J.B. Grant M.D.¹ and M. Jeffery Mador M.D.¹,³.

Institutions:
1. State University of New York at Buffalo, Buffalo, NY, USA
2. Faxton-St. Luke's Hospital, Utica, NY, USA
3. Veteran Affairs Medical Center, Buffalo, New York

Corresponding Author:
M. Jeffery Mador M.D.,
Division of Pulmonary, Critical Care and Sleep Medicine,
Section 111S
3495 Bailey Avenue,
Buffalo, New York 14215
Phone: 716-862-8635
Fax: 716-862-8632
Email: mador@buffalo.edu
Abstract:

Objective: Auto-titrating continuous positive airway pressure (Auto-CPAP) devices now have a smart card (a pocket-sized card with embedded integrated circuits which records data from the CPAP machine such as CPAP usage, CPAP pressure, large leak, etc.) which can estimate the Apnea-Hypopnea Index (AHI) on therapy. The aim of this study was to determine the accuracy of auto-CPAP in estimating the residual AHI in patients with obstructive sleep apnea (OSA) who were treated with auto-CPAP without a CPAP titration study.

Methods: We studied 99 patients with OSA from 4/2005 to 5/2007 who underwent a repeat sleep study using auto-CPAP. The estimated AHI from auto-CPAP was compared with the AHI from an overnight polysomnogram (PSG) on auto-CPAP using Bland-Altman plot and likelihood ratio analyses. A PSG AHI cutoff of 5 events per hour was used to differentiate patients optimally treated with auto-CPAP from those with residual OSA on therapy.

Results: Bland and Altman analysis showed good agreement between auto CPAP AHI and PSG AHI. There was no significant bias when smart card estimates of AHI at home were compared to smart card estimates obtained in the sleep laboratory. An auto-CPAP cutoff for the AHI of 6 events per hour was shown to be optimal for differentiating patients with and without residual OSA with a sensitivity of 0.92 (95% CI: 0.76 to 0.98) and specificity of 0.90 (95% CI: 0.82 to 0.95) with a positive likelihood ratio (LR) of 9.6 (95% CI: 5.1 to 21.5) and a negative likelihood ratio of 0.085 (95% CI: 0.02 to 0.25). Auto-CPAP AHI of 8 events per hour yielded the optimal sensitivity (0.94, 95% CI: 0.73 to 0.99) and specificity (0.90, 95% CI: 0.82 to 0.95) with a
positive LR of 9.6 (95% CI: 5.23 to 20.31) and a negative LR of 0.065 (95%CI: 0.004 to 0.279) to identify patients with a PSG AHI ≥ 10 events per hour.

Conclusion:

Auto-CPAP estimate of AHI may be used to estimate residual AHI in patients with OSA of varying severity treated with auto-CPAP.
Keywords:
Auto-CPAP, Apnea-Hypopnea Index, Obstructive Sleep Apnea, Residual Apnea-Hypopnea Index, Residual Obstructive Sleep Apnea, Smart Card
Abbreviations:

AHI: Apnea-Hypopnea Index
AASM: American Academy of Sleep Medicine
BMI: Body Mass Index
CI: Confidence Interval
CSA: Central Sleep Apnea
CPAP: Continuous Positive Airway Pressure
CHF: Congestive Heart Failure
COPD: Chronic Obstructive Pulmonary Disease
ESS: Epworth Sleepiness Scale
OSA: Obstructive Sleep Apnea
PSG: Polysomnogram
RDI: Respiratory Disturbance Index
SD: Standard Deviation
INTRODUCTION

Obstructive sleep apnea syndrome (OSA) is highly prevalent in middle age populations and can interfere with quality of life and increase morbidity and mortality [1, 2]. Continuous positive airway pressure (CPAP) is a standard, safe, and efficacious treatment for patients with OSA [3]. Conventionally, the pressure applied during long term treatment is determined manually by a technician during attended polysomnographic recording. This allows adjusting pressures to find a setting that essentially eliminates apneas and hypopneas in all sleep stages and body positions. In-lab CPAP titration also allows direct observation by trained technologists to guide pressure selection, to adjust mask fit, to eliminate leak, and to help the patient adapt to the initial CPAP experience [4]. However, there are some potential limitations associated with polysomnogram (PSG)-directed CPAP determinations like the cost and inconvenience of repeat PSG, the potential bias of in-laboratory versus in-home environment, and the potential to prescribe pressures that are not optimal due to results based on one night of study [5]. At home auto-CPAP titration has been introduced as a practical strategy that can reduce the time to effective treatment and reduce costs [6, 7]. The American Academy of Sleep Medicine (AASM) has issued practice parameters for the use of auto-CPAP devices for treating patients with OSA and have stated that auto-CPAP devices may be initiated and used in the self-adjusting mode for unattended treatment of patients with moderate to severe OSA without significant co-morbidities (congestive heart failure, chronic obstructive pulmonary disease, central sleep apnea syndromes or hypoventilation syndromes). This is an optional recommendation which implies inconclusive or conflicting evidence or conflicting expert opinion [5]. The document also states
that certain auto-CPAP devices may be used in an unattended way to determine a fixed CPAP
treatment pressure for patients with moderate to severe OSA without significant co-morbidities
(optional recommendation).

AASM also recommended that patients being treated with auto-CPAP must have close
clinical follow up to determine treatment effectiveness and safety. A reevaluation or a standard
attended CPAP titration should be performed if symptoms do not resolve or if the auto-CPAP
treatment otherwise appears to lack efficacy [5]. Approximately two thirds of newly diagnosed
patients with OSA at our institution (Veterans Affairs Medical Center at Buffalo) are being
started on auto-CPAP treatment to avoid in-lab CPAP titration studies and to improve overall
access to sleep lab services. One potential way to determine efficacy of treatment objectively at
home is to follow the estimated residual AHI from the smart card which is a part of newer
generation auto-CPAP devices. A smart card is a pocket-sized card with embedded integrated
circuits which records data from the CPAP machine such as CPAP usage, CPAP pressure, large
leak, etc. and can estimate the Apnea-Hypopnea Index (AHI) on therapy using machine specific
event detection algorithms. Sparse data exist to support the finding that the residual AHI
obtained from the auto-CPAP devices is a reliable marker of residual OSA [8].

The aim of our study was to determine the accuracy of auto-CPAP in estimating the
residual AHI in patients with OSA who are being treated with auto-CPAP without a CPAP
titration study.

**PATIENTS AND METHODS**

We analyzed data from 99 patients with OSA seen at Veterans Affairs (VA) Medical
Center at Buffalo who were being treated with auto-CPAP and who returned for an attended in-
lab overnight sleep study using auto-CPAP from April, 2005 to May, 2007. All patients had
obstructive sleep apnea based on an in-lab attended diagnostic PSG. We excluded patients with central sleep apnea (CSA) or combined sleep apnea with predominantly OSA but a central apnea index of ≥ 5 events per hour. The decision to treat the patient with auto-CPAP was made by the treating physician. Patients without a history of snoring were not excluded. Epworth sleepiness scale (ESS) and body mass index (BMI) were recorded at the time of diagnostic PSG for each patient. We also collected information about CPAP compliance, average AHI for the week prior to the study night, mean auto-CPAP pressure, and average leak per minute from the auto-CPAP smart card.

**Polysomnography**

Out of the 99 patients, 92 diagnostic PSGs were performed at the VA Medical Center at Buffalo and 7 studies were done at different sleep labs with a scanned report in the patient’s electronic medical record. All PSGs done at the VA Medical Center were scored manually by the same experienced, certified sleep technician and were reviewed and verified by one of two certified sleep physicians (MJM or BJG). All patients underwent a second attended standard nocturnal polysomnography using the auto-CPAP device in the sleep laboratory at the VA medical center at Buffalo. The Auto CPAP device used by all patients was the Remstar Auto with software version Encore Pro 1.6 (Respironics, Murrysville, PA). All PSG’s were done using the same polysomnography system (Sandman; Nellcor Puritan Bennett: Ottawa, Ontario, Canada). The auto-CPAP device was used from lights off to lights on with the smart card in place and the estimated AHI from the smart card was obtained without the knowledge of the polysomnography scorer until after the manual scoring of the PSG had been completed. Apnea was defined as the absence of airflow for at least 10 seconds. If respiratory
effort was present during this apnea episode, it was defined as an obstructive apnea and when respiratory effort was absent, it was termed a central apnea. Hypopnea was defined as a reduction in airflow lasting at least 10 seconds and associated with either a 4 percent drop in arterial oxyhemoglobin saturation or an electroencephalogram arousal. An arousal was defined according to the criteria proposed by the Atlas Task Force [9]. The severity of sleep apnea on diagnostic PSG was classified as follows: mild, AHI ≥ 5 to < 15 events per hour; moderate, AHI ≥ 15 to < 30 events per hour; and severe, AHI ≥ 30 events per hour. Residual OSA was defined as an AHI ≥ 5 events per hour on PSG while using auto-CPAP. The estimated AHI from the smart card was compared with the AHI from the overnight PSG. The average estimated AHI from the week prior to the study from the smart card was also compared with the AHI from overnight PSG and with the auto-CPAP AHI from the study night.

**Statistical Analysis**

Numeric variables are presented as arithmetic means ± SD or medians (25th, 75th percentiles) when the data were not normally distributed. Statistical significance was considered to be present when p < 0.05. The PSG from the study night was considered the gold standard for identifying and quantifying apneas and hypopneas during sleep. The accuracy of the auto-CPAP smart card in detecting residual AHI was based on comparisons of the auto-CPAP AHI and the PSG AHI which was evaluated by Spearman’s coefficient of rank correlation (due to non normal distribution of the data), agreement using the method of Bland and Altman [10] (MedCalc® Statistical Software version 9.3.8), and by constructing receiver-operator characteristic (ROC) curves [11] to determine optimal cutoff values for determining positive and negative likelihood ratios. We log transformed the data to improve the scatter of the differences as the AHI increased [10]. To avoid zero value problems with log transformation to base 10, we added 0.1 to
the AHI before log transformation (log 10[AHI+0.1]). The average estimated AHI from the week prior to the study night from the smart card was also compared with PSG AHI and auto-CPAP AHI from the study night using Spearman’s coefficient of rank correlation and Bland-Altman analysis. The area under the receiver operating curve was estimated by the c index.[11]. We also analyzed the ability of auto-CPAP AHI to identify patients with residual OSA as likelihood ratios (NCSS 2007 statistical software). Patients with and without residual OSA on auto-CPAP were compared with t-test: two sample assuming unequal variances using Microsoft Office Excel 2003[12].

The study protocol was approved by the institutional review board of the Western New York Veteran Affairs Healthcare System, Buffalo, New York.

RESULTS

We analyzed data from 99 patients. Patient characteristics are shown in Table 1. The mean age of patients was 56.7 years (range, 25-83) and the mean body mass index (BMI) was 35.0 (range, 22.4-52). Data for AHI and Epworth sleepiness scale (ESS) were available in 92/99 (93%) patients at the time of initial diagnostic PSG. 20 (22%) (19 male, 1 female) patients had mild, 30 (33%) (29 male, 1 female) had moderate and 42 (45%) (41 male and 1 female) had severe OSA as per diagnostic PSG. The mean ESS was 13.4±5.2 and median AHI was 26.3 (16.0, 63.2) events per hour at the time of diagnosis. Sixteen (16%) patients had COPD and five (5%) patients had CHF. None of the patients had obesity hypoventilation syndrome.

Estimated AHI from the auto-CPAP smart card and PSG were obtained and analyzed for all 99 patients. Spearman’s coefficient of rank correlation was 0.74 (p<0.0001, 95% CI: 0.64 to 0.82) for the auto-CPAP AHI and PSG AHI (Figure 1). All residual apneas and hypopneas were
obstructive in nature on PSG study. A Bland-Altman plot of log values of auto-CPAP AHI and PSG AHI is shown in Figure 2a. The scatter of AHI differences was non random. The smart card estimate of AHI overestimated PSG AHI at low values of AHI and tended to underestimate PSG AHI at higher AHI levels. A linear regression of the Bland Altman plot revealed an r-value of 0.69 (p<0.0001) as shown in figure 2b. We constructed ROC curves to assess the sensitivity and specificity of different values of auto-CPAP AHI to identify patients with residual OSA, defined as a PSG AHI ≥ 5 events per hour on auto-CPAP. The area under the ROC curve as estimated by the c index was 0.958, 95% CI 0.920 to 0.997. An auto-CPAP AHI of 6 events per hour yielded the optimal sensitivity (0.92, 95% CI: 0.76 to 0.98) and specificity (0.90, 95% CI: 0.82 to 0.95) with a positive likelihood ratio (LR) of 9.6 (95% CI: 5.1 to 21.5) and a negative likelihood ratio of 0.085 (95% CI: 0.02 to 0.25) (Table 2). An auto-CPAP AHI of 8 events per hour yielded the optimal sensitivity (0.94, 95% CI: 0.73 to 0.99) and specificity (0.90, 95% CI: 0.82 to 0.95) with a positive LR of 9.6 (95% CI: 5.23 to 20.31) and a negative LR of 0.065 (95%CI: 0.004 to 0.279) to identify patients with PSG AHI ≥ 10 events per hour on auto-CPAP (Table 2). Auto-CPAP failed to identify one patient with residual OSA (auto-CPAP AHI 4, PSG AHI 5.1).

We also had data of average estimated AHI for one week prior to the study night from the auto-CPAP smart card on 88 (89%) patients. We compared average smart card AHI to PSG AHI and to auto-CPAP AHI from the study night. Spearman's coefficients of rank correlation were 0.67 (p<0.0001, 95% CI: 0.54 to 0.77) for average AHI and PSG AHI, and 0.86 (p<0.0001, 95% CI: 0.79 to 0.90) for average AHI and auto-CPAP AHI during the study night. Bland-Altman plots of log values of average AHI comparing with PSG AHI, and average AHI comparing with auto-CPAP AHI during the study night are shown in Figure 3a and 3b respectively. The
comparison of the average AHI and PSG AHI also revealed a non random scatter of AHI differences. The average AHI overestimated PSG AHI at low values of AHI and tended to underestimate PSG AHI at higher AHI values. A linear regression of the Bland-Altman plot revealed an \( r \)-value of 0.64 (\( p<0.0001 \)). Comparing the average AHI and study night AHI from the smart card, there was no significant bias and the scatter of the differences was random.

Table 3 shows mean AHI at the time of diagnosis and on auto-CPAP treatment for patients with mild, moderate and severe OSA. 26 (26%) of 99 patients had residual OSA (PSG AHI \( \geq \) 5 events per hour) on auto-CPAP treatment. We compared age, BMI, diagnostic AHI data and auto-CPAP smart card compliance data from patients with residual OSA with those from without residual OSA using t-test: two sample assuming unequal variances (Table 4). Patients without residual OSA were younger \( (p=0.02) \) and had lower BMI \( (p=0.04) \) compared to patients with residual OSA. Patients without residual OSA tended to have better compliance (\% of days with device use, \% of days with >4 hours use) than those with residual OSA, which did not quite reach statistical significance. Average leak per minute was higher in patients with residual OSA compared to those without residual OSA \( (p=0.04) \). Seventeen patients (17\%) had a residual AHI of \( \geq 10 \) events per hour on auto-CPAP treatment.

DISCUSSION

In this study, we assessed the accuracy of auto-CPAP to estimate residual AHI in patients with OSA being treated with auto-CPAP without a CPAP titration study. This is the first reasonably large study \( (n=99) \) conducted to address this question to the best of our knowledge. Woodson et al [8] \( (n=24 \) of which only 8 patients had simultaneous attended PSG) compared auto-CPAP AHI with PSG AHI in patients undergoing unattended home auto-CPAP titration and found that auto CPAP overestimated AHI by an average of 1.4 events per hour when compared
to PSG AHI. The results of our study showed that there is reasonable clinical agreement between
auto-CPAP AHI and PSG AHI and auto CPAP cutoffs can be determined which predict with
accuracy which patients have residual disease on therapy as defined by either a PSG AHI of ≥ 5
events per hour or ≥ 10 events per hour. Bland and Altman plots demonstrate that the difference
between auto-CPAP AHI and PSG AHI was not uniform with auto-CPAP overestimating the
AHI at lower values of AHI and underestimating the AHI at higher values of AHI. There was a
marked underestimation of AHI by auto-CPAP when compared to PSG in two patients. One
patient had an auto-CPAP AHI of 9 events per hour and PSG AHI of 41.1 events per hour, the
other had auto-CPAP and PSG AHIs of 29 events per hour and 52.7 events per hour,
respectively. The first patient had an unsatisfactory PSG study as he slept poorly during the study
night. Auto-CPAP identified a similar number of events during the night but since it cannot
differentiate between sleep and wakefulness, it assumed a longer sleep time than was actually
present, leading to the discrepancy in AHI. In the other patient, no factors were identified that
would explain why the auto-CPAP underestimated the actual AHI. Our study showed that an
auto-CPAP AHI of 6 identified patients with residual OSA (AHI ≥ 5 events per hour) with strong
positive and negative likelihood ratios [13]. This suggests that the auto-CPAP device can be used
to assess the adequacy of therapy with a reasonable level of accuracy.

Our study also showed good clinical agreement between the average smart card AHI
from the week prior to the study night and PSG AHI as well as auto-CPAP AHI from the study
night. The average AHI from the prior week gives perhaps a better estimate of effectiveness of
treatment as it measures the AHI at home and over a period of seven days instead of a one night
value obtained in lab. It also replicates the way clinicians will use this modality in the real world.
Authors would like to emphasize that in-lab PSG titration has some advantages over home
strategies like pressure selection under direct observation by a trained technician, adjusting mask fit, eliminating leak and educating patients; and confirming effectiveness during supine or REM sleep.

Though no widely-accepted definition of residual OSA exists, we used the traditional cutoff point of AHI ≥ 5 events per hour on PSG [2]. The positive airway pressure titration task force of the AASM defines an optimal CPAP titration as an RDI < 5 events per hour for at least 15 minutes which should include supine REM sleep [14]. In this study, we found that almost one in four patients (26%) on auto-CPAP treatment had residual OSA. Although the prevalence of residual OSA in our study may seem high, our findings are consistent with prior investigations. Torre-Bouscoulet et al [15] reported a prevalence of 29% in 279 patients with residual OSA defined as a residual RDI >10 events per hour using an auto-CPAP device. Stammnitz et al [16] also reported a residual OSA prevalence of 17% in a small number of patients, but he defined residual OSA as RDI > 5 events per hour from the auto-CPAP device. Baltzan et al [17] reported a prevalence of 17% using a cut off of AHI ≥ 10 events per hour on PSG in patients treated with fixed pressure CPAP after a CPAP titration study and who had persistent resolution of symptoms. Another study showed that almost one in five patients with good CPAP compliance had residual moderate to severe OSA on their prescribed setting [18]. The long term effects of residual OSA are not fully understood. One study showed that subtherapeutic CPAP did not result in a decrease in mean blood pressure [19]. Peker et al [20] reported that incomplete treatment was not found to be associated with a reduction in the incidence of cardiovascular complications. This high prevalence of residual OSA in patients treated with auto-CPAP or fixed-pressure CPAP after a CPAP titration study stresses the importance of follow-up to determine treatment effectiveness. Clinical follow up alone may not be enough as prevalence of
residual OSA was found to be high even in patients without symptoms [17, 18]. Thus, institution
of auto CPAP with no further evaluation if symptoms improve will not be sufficient if the
therapeutic goal is to avoid residual OSA. However, evaluation of residual AHI by smart card
estimate may be a satisfactory method to avoid residual OSA in treated patients.

In this study, we have not excluded patients with OSA who also had other co morbidities
like CHF, COPD or hypoventilation syndromes. The AASM does not recommend use of auto
CPAP in patients with such co morbidities [5]. None of our patients in this study had
hypoventilation syndromes likely because sleep physicians at our institution did not start
autoCPAP in such patients. Sixteen (16%) patients had COPD and 5 (5%) patients had CHF.

Since patients with central events and/or Cheynes-Stokes breathing during the diagnostic study
were excluded from the study, it is perhaps not surprising that smart card estimates of AHI in the
small number of patients with CHF were reasonably accurate. It is interesting that smart card
estimates of AHI were no less accurate in patients with COPD than in the rest of the study group.

However, the small number of such patients precludes definitive conclusions and further study is
required in this patient population.

A limitation of our study is that only one manufacturer’s auto-CPAP device was used for
the study. Different auto CPAP devices use different algorithms to detect AHI and they may
have different detection rates [21,22]. The CPAP device employed in this study adjusts pressure
based on analysis of flow (looking for flow limitation) and presence of snoring [22]. Some
devices also measure upper airway resistance using the forced oscillation technique [21,22].
Thus, the results of this study may only be applicable to the auto-CPAP device employed in this
study. Another limitation is that the smart card only provides an estimate of the AHI on therapy.

There is no assessment of oxygen saturation levels. If hypoxemia was prominent in the
diagnostic study, further assessment may be required to ensure that hypoxemia has been resolved with therapy.

In conclusion, auto-CPAP AHI may be used to estimate residual AHI in patients with varying severity of OSA being treated with auto-CPAP without a CPAP titration study provided its limitations in accuracy are understood. Average auto-CPAP AHI from prior week’s use at home was not less accurate than the estimate of AHI obtained from auto-CPAP during the overnight sleep study. Based on the likelihood ratios, auto CPAP yielded a large increase in the probability of residual OSA (PSG AHI $\geq 5$ events per hour) when the auto CPAP AHI was $\geq 6$ events per hour and a large reduction in the probability of residual OSA when the auto CPAP AHI was $< 6$ events per hour [13]. Thus, auto-CPAP AHI can be used to assess the adequacy of therapy in patients with OSA with reasonable level of accuracy.

ACKNOWLEDGEMENTS

Funding: None

Work was performed at: Western New York Veteran Affairs Healthcare System, Buffalo, New York
Himanshu Desai, M.D., has no financial or personal conflict of interest in presenting this manuscript.

Anil Patel, M.D., has no financial or personal conflict of interest in presenting this manuscript.

Pinal Patel, M.B.B.S., has no financial or personal conflict of interest in presenting this manuscript.

Brydon J. B. Grant, M.D., has no financial or personal conflict of interest in presenting this manuscript.

M Jeffrey Mador, M.D., has no financial or personal conflict of interest in presenting this manuscript.

References


Table 1. Characteristics of the Study Population

<table>
<thead>
<tr>
<th></th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients*</td>
<td>20</td>
<td>30</td>
<td>42</td>
<td>99</td>
</tr>
<tr>
<td>Male</td>
<td>19</td>
<td>29</td>
<td>41</td>
<td>96</td>
</tr>
<tr>
<td>Female</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Age at Diagnostic PSG</td>
<td>54.4 ± 11.4</td>
<td>56.3 ± 13.9</td>
<td>57.4 ± 9.7</td>
<td>56.7 ± 11.3</td>
</tr>
<tr>
<td>BMI at Diagnostic PSG</td>
<td>33.0 ± 5.1</td>
<td>33.1 ± 5.4</td>
<td>36.8 ± 6.7</td>
<td>35.0 ± 6.3</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>ESS at Diagnostic PSG</td>
<td>13.2 ± 4.9</td>
<td>13.0 ± 5.4</td>
<td>13.8 ± 5.2</td>
<td>13.4 ± 5.2†</td>
</tr>
<tr>
<td>AHI at Diagnosis</td>
<td>11.0 ± 2.5</td>
<td>20.3 ± 4.3</td>
<td>66.1 ± 25.2</td>
<td>26.3 (16.0, 63.2)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>13 (65%)</td>
<td>24 (80%)</td>
<td>32 (76%)</td>
<td>74 (75%)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>6 (30%)</td>
<td>13 (43%)</td>
<td>17 (40%)</td>
<td>40 (40%)</td>
</tr>
<tr>
<td>CAD</td>
<td>5 (25%)</td>
<td>6 (20%)</td>
<td>12 (29%)</td>
<td>4 (24%)</td>
</tr>
<tr>
<td>COPD</td>
<td>3 (15%)</td>
<td>4 (13%)</td>
<td>8 (19%)</td>
<td>16 (16%)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>2 (10%)</td>
<td>1 (3%)</td>
<td>5 (12%)</td>
<td>10 (10%)</td>
</tr>
<tr>
<td>Obesity</td>
<td>9 (45%)</td>
<td>9 (30%)</td>
<td>26 (62%)</td>
<td>45 (45%)</td>
</tr>
<tr>
<td>CHF</td>
<td>0 (0%)</td>
<td>1 (3%)</td>
<td>4 (10%)</td>
<td>5 (5%)</td>
</tr>
</tbody>
</table>

Table 2. Sensitivity, Specificity, and Likelihood ratios

<table>
<thead>
<tr>
<th>PSG AHI</th>
<th>APAP AHI</th>
<th>Sens</th>
<th>Spec</th>
<th>+ LR</th>
<th>Lower CI</th>
<th>Upper CI</th>
<th>- LR</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>6</td>
<td>0.92</td>
<td>0.90</td>
<td>9.6</td>
<td>5.1</td>
<td>21.5</td>
<td>0.085</td>
<td>0.02</td>
<td>0.25</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>0.94</td>
<td>0.90</td>
<td>9.6</td>
<td>5.23</td>
<td>20.31</td>
<td>0.065</td>
<td>0.004</td>
<td>0.279</td>
</tr>
</tbody>
</table>

PSG (Polysomnogram), BMI (Body Mass Index), ESS (Epworth Sleepiness Scale), CAD (Coronary Artery Disease), COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure)

Age, BMI and ESS passed normality test and are presented as means ± 1SD. AHI for mild, moderate and severe OSA passed normality test, but total AHI did not and hence presented as median with 25th and 75th percentiles.

† Missing data of ESS in 7 patients, * the AHI of patients with outside diagnostic studies not included in Table..
Table 3. AHI at Diagnosis and on Auto-CPAP Treatment

<table>
<thead>
<tr>
<th></th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Total*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AHI at Diagnosis</strong></td>
<td>11.0±2.5</td>
<td>21.0±4.3</td>
<td>66.0±25.2</td>
<td>26.3(16.0, 63.2)</td>
</tr>
<tr>
<td></td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
<td>Total</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------</td>
<td>----------</td>
<td>--------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>AHI on auto-CPAP from smart card</strong></td>
<td>5.9±6.1</td>
<td>6.4±6.7</td>
<td>7.3±6.9</td>
<td>4.1(3.0, 8.5)</td>
</tr>
<tr>
<td><strong>AHI on auto-CPAP from PSG</strong></td>
<td>2.5±3.9</td>
<td>4.8±10.3</td>
<td>6.6±10.3</td>
<td>1.6(0.3, 6.1)</td>
</tr>
</tbody>
</table>

Presented as mean ± SD for mild, moderate and severe; median (25th, 75th percentile) for total

**Table 4. Characteristics of Patients With and Without Residual OSA on Auto-CPAP**
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients with residual OSA, AHI ≥ 5 on auto-CPAP (n=26, 26%)</th>
<th>Patients without residual OSA, AHI &lt;5 on auto-CPAP (n=73, 74%)</th>
<th>t Critical two-tail</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>58.92 ± 12.13</td>
<td>55.32 ± 12.03</td>
<td>2.00</td>
<td>0.02</td>
</tr>
<tr>
<td>BMI</td>
<td>37 ± 6.6</td>
<td>34 ± 6.1</td>
<td>2.02</td>
<td>0.04</td>
</tr>
<tr>
<td>AHI at Diagnosis</td>
<td>38.67 ± 24.56</td>
<td>37.6 ± 31.36</td>
<td>2.01</td>
<td>0.29</td>
</tr>
<tr>
<td>PLMI at Diagnosis</td>
<td>17.44 ± 27.03</td>
<td>20.56 ± 31.17</td>
<td>2.01</td>
<td>0.52</td>
</tr>
<tr>
<td>% of Days with Device Use</td>
<td>73.63 ± 29.29</td>
<td>83.73 ± 24.2</td>
<td>2.04</td>
<td>0.07</td>
</tr>
<tr>
<td>Average use for days used in Min.</td>
<td>298.83 ± 129.0</td>
<td>384.45 ± 309.49</td>
<td>1.99</td>
<td>0.08</td>
</tr>
<tr>
<td>Average Leak (milliliters per Minute)</td>
<td>38.06 ± 55.1</td>
<td>16.47 ± 31.82</td>
<td>2.06</td>
<td>0.04</td>
</tr>
<tr>
<td>Mean Auto CPAP pressure from prior week (cm H2O)</td>
<td>8.34 ± 2.32</td>
<td>7.94 ± 2.14</td>
<td>2.09</td>
<td>0.56</td>
</tr>
<tr>
<td>% of Days with &gt;4 Hrs. Use</td>
<td>49.91 ± 36.32</td>
<td>64.79 ± 31.15</td>
<td>2.04</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Characteristics Presented as means ± SD. AHI: Apnea-Hypopnea Index, BMI: Body Mass Index, PSG: Polysomnogram, PLMI: Periodic Leg Movement Index
Figure 1. Scatter plot of PSG AHI and auto-CPAP AHI

Spearman’s coefficient of rank correlation is 0.74 (p<0.0001, 95% CI 0.64 to 0.82) for PSG AHI and auto-CPAP AHI.
Figure 2a. Bland-Altman plot of auto-CPAP AHI and PSG AHI (Logarithmic transformation)

Log 10(AHI+0.1) values used. The scatter of the differences was non random.
Figure 2b. Linear regression of difference between log values of auto-CPAP and PSG AHI with average of log values of auto-CPAP and PSG AHI

Log 10(AHI+0.1) values used. r=0.69 (p<0.0001)
Figure 3a. Bland-Altman plot of average smart card AHI and PSG AHI (Logarithmic transformation)

Log 10(AHI+0.1) values used. The scatter of the differences was non random. The difference between auto-CPAP AHI and PSG AHI was significantly correlated with the average of auto-CPAP AHI and PSG AHI (r=0.64, p<0.0001)
Figure 3b. Bland-Altman plot of average smart card AHI and auto-CPAP AHI

(Logarithmic transformation)

Log 10(AHI+0.1) values used. Mean difference (bias) of 0.2 (95% CI: 0.17 to 0.25). The scatter of the differences was random (r=0.15, p=0.15)